Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86XF0
UPID:
DYR2_HUMAN
Alternative names:
Dihydrofolate reductase, mitochondrial; Dihydrofolate reductase-like protein 1
Alternative UPACC:
Q86XF0; D3DN30; Q6P4I9
Background:
Dihydrofolate reductase 2, mitochondrial, also known as Dihydrofolate reductase-like protein 1, plays a pivotal role in folate metabolism. It is essential for the de novo mitochondrial thymidylate biosynthesis pathway, crucial for DNA replication and repair. This enzyme's unique function includes preventing uracil accumulation in mitochondrial DNA (mtDNA) and regulating its own mRNA along with that of DHFR.
Therapeutic significance:
Understanding the role of Dihydrofolate reductase 2, mitochondrial could open doors to potential therapeutic strategies. Its critical function in folate metabolism and DNA synthesis positions it as a key target for developing treatments aimed at mitochondrial diseases and disorders related to folate metabolism dysregulation.